{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:49:33Z","timestamp":1760906973051},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T00:00:00Z","timestamp":1344470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl J Gynecology &amp; Obste"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the efficacy and toxicity of 3 single agent chemotherapeutic regimens in low\u2010risk gestational trophoblastic neoplasia (LRGTN).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective study was conducted at a referral center in Rio de Janeiro, Brazil. Patients presenting with metastatic or non\u2010metastatic LRGTN (risk score \u2264 6) in non\u2010probabilistic sampling were assigned to 1 of 3 treatments: methotrexate with folinic acid rescue (MTX\u2010CF; n = 20); actinomycin D (n = 20); and etoposide (n = 20). Women with less than 1 year of disease\u2010free follow\u2010up after the first normal human chorionic gonadotropin (hCG) value were excluded. Outcome measures included primary remission rate; resistance to primary and sequential chemotherapy; period between treatment initiation and remission (hCG response); and prevalence of toxic effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Primary remission was achieved by 48 patients (80.0%). The remission rate with etoposide was 100.0%, while the rates with actinomycin D and MTX\u2010CF were 90.0% and 50.0%, respectively. Efficacy of etoposide was significantly greater than the other 2 agents (<jats:italic>P<\/jats:italic> &lt; 0.001). Alopecia was the most frequent adverse effect caused by etoposide. Common to all protocols were stomatitis, nausea, and vomiting. Mean time intervals between beginning treatment and remission were similar and all 60 participants survived.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Etoposide was the most effective regimen for treating metastatic and non\u2010metastatic LRGTN.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.ijgo.2012.04.027","type":"journal-article","created":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T05:03:19Z","timestamp":1344488599000},"page":"35-38","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of methotrexate, actinomycin D, and etoposide for treating low\u2010risk gestational trophoblastic neoplasia"],"prefix":"10.1002","volume":"119","author":[{"given":"Angela M.","family":"Baptista","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Belfort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,8,9]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"327","volume-title":"Epidemiology Features of Gestational Trophoblastic Neoplasia in Rio de Janeiro and in Goiania, Brazil Proceedings of the XII World Congress of Gynecology and Obstetrics, vol. 3","author":"Belfort P.","year":"1988"},{"key":"e_1_2_6_3_2","first-page":"27","volume-title":"Gestational Trophoblastic Neoplasia. Controversies","author":"Belfort P.","year":"2007"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)01245-2"},{"key":"e_1_2_6_5_2","first-page":"14","volume-title":"Histological Typing of Soft Tissue Tumours","author":"Scully R.E.","year":"1994"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(02)00063-2"},{"issue":"6","key":"e_1_2_6_7_2","first-page":"445","article-title":"Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report","volume":"47","author":"Kohorn E.I.","year":"2002","journal-title":"J Reprod Med"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1048-891X.2004.014236.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.00898.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(82)90400-8"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19871101)60:9<2173::AID-CNCR2820600910>3.0.CO;2-3"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(90)90108-W"},{"issue":"3","key":"e_1_2_6_13_2","first-page":"413","article-title":"Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease","volume":"72","author":"Homesley H.D.","year":"1988","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)90575-8"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"issue":"1","key":"e_1_2_6_16_2","first-page":"1","article-title":"Hydatidiform mole: diagnosis, management, and long\u2010term followup of 347 patients","volume":"45","author":"Curry S.L.","year":"1975","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92641-T"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-200309000-00007"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000009987"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601422"},{"issue":"8","key":"e_1_2_6_21_2","first-page":"602","article-title":"What is the best regimen for low\u2010risk gestational trophoblastic neoplasia? A review","volume":"49","author":"Osborne R.","year":"2004","journal-title":"J Reprod Med"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.166"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(96)70229-6"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-200309000-00010"}],"container-title":["International Journal of Gynecology &amp; Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S002072921200344X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S002072921200344X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ijgo.2012.04.027","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ijgo.2012.04.027","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.ijgo.2012.04.027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T05:27:09Z","timestamp":1696483629000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1016\/j.ijgo.2012.04.027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,9]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1016\/j.ijgo.2012.04.027"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgo.2012.04.027","archive":["Portico"],"relation":{},"ISSN":["0020-7292","1879-3479"],"issn-type":[{"value":"0020-7292","type":"print"},{"value":"1879-3479","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,9]]}}}